Kuros Biosciences Valuation
| CSBTF Stock | USD 21.40 3.90 15.42% |
At this time, the firm appears to be fairly valued. Kuros Biosciences secures a last-minute Real Value of $20.88 per share. The latest price of the firm is $21.4. Our model forecasts the value of Kuros Biosciences from analyzing the firm fundamentals such as Current Valuation of 40.53 M, return on equity of -0.14, and Profit Margin of (0.74) % as well as examining its technical indicators and probability of bankruptcy.
Fairly Valued
Today
Please note that Kuros Biosciences' price fluctuation is somewhat reliable at this time. Calculation of the real value of Kuros Biosciences is based on 3 months time horizon. Increasing Kuros Biosciences' time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
The fair value of the Kuros pink sheet is determined by what a typical buyer is willing to pay for full or partial control of Kuros Biosciences AG. Since Kuros Biosciences is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Kuros Pink Sheet. However, Kuros Biosciences' intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 21.4 | Real 20.88 | Hype 21.4 | Naive 20.09 |
The real value of Kuros Pink Sheet, also known as its intrinsic value, is the underlying worth of Kuros Biosciences Company, which is reflected in its stock price. It is based on Kuros Biosciences' financial performance, growth prospects, management team, or industry conditions. The intrinsic value of Kuros Biosciences' stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, or news.
Estimating the potential upside or downside of Kuros Biosciences AG helps investors to forecast how Kuros pink sheet's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Kuros Biosciences more accurately as focusing exclusively on Kuros Biosciences' fundamentals will not take into account other important factors: Kuros Biosciences Total Value Analysis
Kuros Biosciences AG is currently anticipated to have takeover price of 40.53 M with market capitalization of 70.16 M, debt of 2.21 M, and cash on hands of 28.62 M. Please note that takeover price may be misleading and is a subject to mistakes in financial statements. We encourage investors to thoroughly investigate all of the Kuros Biosciences fundamentals before making investing decisions based on enterprise value of the company| Takeover Price | Market Cap | Debt Obligations | Cash |
40.53 M | 70.16 M | 2.21 M | 28.62 M |
Kuros Biosciences Investor Information
About 35.0% of the company shares are held by company insiders. The company has price-to-book (P/B) ratio of 0.79. Some equities with similar Price to Book (P/B) outperform the market in the long run. Kuros Biosciences recorded a loss per share of 0.24. The entity had not issued any dividends in recent years. The firm had 1:100 split on the 23rd of June 2016. Based on the key indicators related to Kuros Biosciences' liquidity, profitability, solvency, and operating efficiency, Kuros Biosciences AG is not in a good financial situation at this time. It has a very high probability of going through financial hardship in February.Kuros Biosciences Asset Utilization
The asset utilization indicator refers to the revenue earned for every dollar of assets a company currently reports. Kuros Biosciences has an asset utilization ratio of 15.13 percent. This implies that the Company is making $0.15 for each dollar of assets. An increasing asset utilization means that Kuros Biosciences AG is more efficient with each dollar of assets it utilizes for everyday operations.Kuros Biosciences Ownership Allocation
Kuros Biosciences maintains a total of 36.54 Million outstanding shares. Kuros Biosciences AG holds significant amount of outstanding shares owned by insiders. An insider is usually defined as a CEO, other corporate executive, director, or institutional investor who own at least 10% of the company's outstanding shares. Please note that no matter how many assets the company has, if the real value of the firm is less than the current market value, you may not be able to make money on it.Kuros Biosciences Profitability Analysis
The company reported the revenue of 13.81 M. Net Loss for the year was (7.54 M) with profit before overhead, payroll, taxes, and interest of 10.07 M.Please note that valuation analysis is one of the essential comprehensive assessments in business. It evaluates Kuros Biosciences' worth, which you can determine by considering its current assets, liabilities and future cash flows. The investors' valuation analysis is an important metric that will give you a perspective on different companies. It helps you know the worth of the potential investment in Kuros Biosciences and how it compares across the competition.
About Kuros Biosciences Valuation
The pink sheet valuation mechanism determines Kuros Biosciences' current worth on a weekly basis. Our valuation model uses a comparative analysis of Kuros Biosciences. We calculate exposure to Kuros Biosciences's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of Kuros Biosciences's related companies.Kuros Biosciences AG, a biopharmaceutical company, engages in the commercialization and development of biopharmaceutical products for tissue repair and bone regeneration in the United States, the European Union, and internationally. It has collaboration with Checkmate Pharmaceuticals LLC for the development of CYT003 for the treatment of oncology. KUROS BIOSCIENCES operates under Biotechnology classification in the United States and is traded on PNK Exchange. It employs 58 people.
8 Steps to conduct Kuros Biosciences' Valuation Analysis
Company's valuation is the process of determining the worth of any company in monetary terms. It estimates Kuros Biosciences' potential worth based on factors such as financial performance, market conditions, growth prospects, and overall economic environment. The result of company valuation is a single number representing a Company's current market value. This value can be used as a benchmark for various financial transactions such as mergers and acquisitions, initial public offerings (IPOs), or private equity investments. To conduct Kuros Biosciences' valuation analysis, follow these 8 steps:- Gather financial information: Obtain Kuros Biosciences' financial statements, including balance sheets, income statements, and cash flow statements.
- Determine Kuros Biosciences' revenue streams: Identify Kuros Biosciences' primary sources of revenue, including products or services offered, target markets, and pricing strategies.
- Analyze market data: Research Kuros Biosciences' industry and market trends, including the size of the market, growth rate, and competition.
- Establish Kuros Biosciences' growth potential: Evaluate Kuros Biosciences' management, business model, and growth potential.
- Determine Kuros Biosciences' financial performance: Analyze its financial statements to assess its historical performance and future potential.
- Choose a valuation method: Consider the Company's specific circumstances and choose an appropriate valuation method, such as the discounted cash flow (DCF) or comparable analysis method.
- Calculate the value: Apply the chosen valuation method to the financial information and market data to calculate Kuros Biosciences' estimated value.
- Review and adjust: Review the results and make necessary adjustments, considering any relevant factors that may have been missed or overlooked.
Kuros Biosciences Growth Indicators
Investing in growth stocks can be very risky. If the company such as Kuros Biosciences does not do well, investors take a loss on the stock when it is time to sell. Also, because growth stocks typically do not pay dividends, the only opportunity an investor has to make money on their investment is when they eventually sell their shares.
| Common Stock Shares Outstanding | 32.8 M | |
| Retained Earnings | -101.6 M | |
| Shares Float | 21.6 M |
Complementary Tools for Kuros Pink Sheet analysis
When running Kuros Biosciences' price analysis, check to measure Kuros Biosciences' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Kuros Biosciences is operating at the current time. Most of Kuros Biosciences' value examination focuses on studying past and present price action to predict the probability of Kuros Biosciences' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Kuros Biosciences' price. Additionally, you may evaluate how the addition of Kuros Biosciences to your portfolios can decrease your overall portfolio volatility.
| Top Crypto Exchanges Search and analyze digital assets across top global cryptocurrency exchanges | |
| Latest Portfolios Quick portfolio dashboard that showcases your latest portfolios | |
| Money Managers Screen money managers from public funds and ETFs managed around the world | |
| Portfolio Holdings Check your current holdings and cash postion to detemine if your portfolio needs rebalancing | |
| Sync Your Broker Sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors. | |
| ETFs Find actively traded Exchange Traded Funds (ETF) from around the world | |
| Portfolio Dashboard Portfolio dashboard that provides centralized access to all your investments |